As of 2025, retatrutide remains an investigational medicine and is not yet approved for clinical use in the United Kingdom
Patients diagnosed with T2DM have an increased risk of both cardiovascular and neurological diseases
In reality, the roundabout money trail keeps patients in the dark about the true cost of coveragea disconnect that relieves incentives for insurers to negotiate better deals with providers
Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, et al
These medications deliver consistent dosing and predictable results when combined with proper medical supervision
33 Tirzepatide Tirzepatide (a dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonist) safety was evaluated in a meta-regression study that established individual adverse event rates at weekly doses of 5, 10 and 15 mg